Page last updated: 2024-11-06

3'-deoxyadenosine 5'-triphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

3'-deoxyadenosine 5'-triphosphate (3'-dATP) is a synthetic analog of adenosine triphosphate (ATP) in which the 3'-hydroxyl group of the ribose moiety is replaced with a hydrogen atom. This modification prevents the formation of a phosphodiester bond at the 3'-position, making 3'-dATP a chain terminator in DNA synthesis. It is commonly used in DNA sequencing, PCR, and other molecular biology techniques to determine the sequence of DNA. 3'-dATP is also used as a substrate for some DNA polymerases, such as terminal deoxynucleotidyl transferase (TdT), which can add 3'-dATP to the 3'-end of DNA strands. The use of 3'-dATP in these applications is based on its ability to be incorporated into DNA by DNA polymerases but not to be extended by the same enzymes. 3'-dATP is typically synthesized via chemical methods involving the phosphorylation of 3'-deoxyadenosine, a nucleoside analog that is obtained by chemical modification of adenosine. 3'-dATP has also been shown to have antiviral activity against certain viruses, such as HIV and herpes simplex virus. This activity is likely due to its ability to inhibit viral DNA replication.'

Cross-References

ID SourceID
PubMed CID65562
CHEMBL ID480329
CHEBI ID52316
SCHEMBL ID250251
MeSH IDM0058276

Synonyms (35)

Synonym
3AT ,
3'-deoxyadenosine-5'-triphosphate
{[(2s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxyoxolan-2-yl]methoxy}(hydroxyphosphoryl) dihydrogen phosphate
[[(2s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate
3'datp
1XFV ,
DB01860
cordycepin triphosphate
73-04-1
CHEBI:52316 ,
cotp
3'-deoxyadenosine 5'-triphosphate
3'-deoxyadenosine 5'-(tetrahydrogen triphosphate)
[[(2s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
3'-datp
CHEMBL480329
bdbm86487
atp,3'-deoxy
59p84zu54h ,
adenosine 5'-(tetrahydrogen triphosphate), 3'-deoxy-
unii-59p84zu54h
71997-32-5
SCHEMBL250251
adenosine, 3'-deoxy-, 5'-triphosphate
adenosine, 3'-deoxy-, 5'-(tetrahydrogen triphosphate)
cordycepin 5'-triphosphate
3'-deoxy-atp
3'-deoxyadenosine triphosphate
3'-deoxyribofuranosyladenine 5'-triphosphate
cordycepin, triphosphate
cordycepin triphosphate [mi]
cordycepin 5-triphosphate sodium salt
((2s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate
3-deoxyadenosine 5-triphosphate sodium salt
DTXSID501014467
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antiviral agentA substance that destroys or inhibits replication of viruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
purine ribonucleoside 5'-triphosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RNA-directed RNA polymerase IC50 (µMol)8.80000.01902.52798.8000AID340760
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Calmodulin-sensitive adenylate cyclaseBacillus anthracisKd130.0000130.0000130.0000130.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1811Experimentally measured binding affinity data derived from PDB2005The EMBO journal, Mar-09, Volume: 24, Issue:5
Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2005The EMBO journal, Mar-09, Volume: 24, Issue:5
Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor.
AID1537215Inhibition of ZIKV N-terminal His6-tagged NS5 protein expressed in Escherichia coli using (Poly U) RNA template after 20 mins in presence of ATP by picogreen dye based assay2019Journal of natural products, 02-22, Volume: 82, Issue:2
Antiviral Compounds from Codiaeum peltatum Targeted by a Multi-informative Molecular Networks Approach.
AID340758Inhibition of HCV NS5B polymerase assessed as chain termination of RNA synthesis2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase.
AID340761Ratio of IC50 for HCV NS5B polymerase S282T mutant to IC50 for HCV NS5B polymerase by single-nucleotide incorporation assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase.
AID1674507Inhibition of DENV RNA-dependent RNA polymerase at 10 uM2020Journal of natural products, 08-28, Volume: 83, Issue:8
Carneic Acids from an Endophytic
AID1537216Inhibition of DENV2 N-terminal His6-tagged NS5 protein expressed in Escherichia coli using (Poly U) RNA template after 20 mins in presence of ATP by picogreen dye based assay2019Journal of natural products, 02-22, Volume: 82, Issue:2
Antiviral Compounds from Codiaeum peltatum Targeted by a Multi-informative Molecular Networks Approach.
AID340760Inhibition of HCV NS5B polymerase S282T mutant assessed as blocking of full length RNA product formation by single-nucleotide incorporation assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase.
AID340759Inhibition of HCV NS5B polymerase assessed as blocking of full length RNA product formation by single-nucleotide incorporation assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (41.18)18.7374
1990's3 (8.82)18.2507
2000's10 (29.41)29.6817
2010's5 (14.71)24.3611
2020's2 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.84 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index1.00 (0.95)

This Compound (24.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.94%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]